
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Lepu Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
DP Technology Collaborates with Lepu Biopharma to Boost ADC Drug Innovation
Details : The partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform and advancing the candidate ADC to the clinical stage.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Lepu Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DPT0416
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DP Technology Nominates CNS-Penetrable LP-PLA2 Inhibitor For Alzheimer's Disease
Details : DPT0416 is a novel CNS penetrable small molecule targeting Lp-PLA2, being investigated for the treatment of Alzheimer's disease (AD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : DPT0416
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DPT0218
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DP Technology Nominates Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor
Details : DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor. It is being evaluated in preclinical studies for the treatment of Inflammatory Bowel Disease & Atopic Dermatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2024
Lead Product(s) : DPT0218
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
